Shots:

• The US FDA approval is based on the clinical study assessing Abrilada (adalimumab-afzb) vs reference product- AbbVie’s Humira in 597 biologic-naïve patients with rheumatoid arthritis for 78 wks.
• Result: @26wks. patients achieved ACR20 (68.7% vs 72.7%) with a treatment difference of −3.98%- ACR20- 50- and 70 rates were similar with both groups
• The approval of Abrilada- a biosimilar to Humira foster the biologics competition in the US as it marks the 9^th biosimilar product to be approved in the US in 2019- bringing the overall total of biosimilar approvals to 25

Click here to­ read full press release/ article | Ref: FDA | Image: Financial Express